Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France

Camille Buffet; Lisa Belin; Roberto Attanasio; Roberto Negro; Lazlo Hegedüs; Endre V. Nagy; Enrico Papini; Petros Perros; Laurence Leenhardt

doi:10.1016/j.ando.2021.11.002

Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France

Translated title of the contribution: Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France

Camille Buffet^*
, Lisa Belin
, Roberto Attanasio
, Roberto Negro
, Lazlo Hegedüs
, Endre V. Nagy
, Enrico Papini
, Petros Perros
, Laurence Leenhardt

^*Corresponding author for this work

KI, OUH, Research unit of Endocrinology (Odense)

Pierre and Marie Curie University
International Chapter of Clinical Endocrinology
V. Fazzi Hospital
University of Debrecen
Regina Apostolorum Hospital
Royal Victoria Infirmary

Research output: Contribution to journal › Journal article › Research › peer-review

73 Downloads (Pure)

Abstract

Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.

Translated title of the contribution	Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France
Original language	French
Journal	Annales d'Endocrinologie
Volume	83
Issue number	1
Pages (from-to)	27-34
ISSN	0003-4266
DOIs	https://doi.org/10.1016/j.ando.2021.11.002
Publication status	Published - Feb 2022

Bibliographical note

Publisher Copyright:
© 2021

Funding

We thank all members of the French Endocrine Society, who contributed to the study by answering the questionnaire. We thank Prof Nicolas Chevalier for his technical support to launch the survey in France. We thank Prof V?ronique Kerlan, president of the French Endocrine Society on behalf of this society, for its support to this project. We thank Fabiana Pani for English proofreading. We thank Fran?oise Borson Chazot, Philippe Caron and Lionel Groussin for their careful reading of the manuscript and their feedback. Laurence Leenhardt has received consulting fees for Merck, research funding from Merck Serono SAS (Lyon, France) and honoraria for lectures from Laboratoires Genevrier (Antibes, France).

Keywords

Adult
Drug Therapy, Combination
Female
France
Humans
Hypothyroidism/drug therapy
Male
Middle Aged
Practice Patterns, Physicians'/statistics & numerical data
Surveys and Questionnaires
Thyroxine/administration & dosage

Documents & Links

10.1016/j.ando.2021.11.002

Open Access VersionAccepted manuscript, 1.51 MBLicence: CC BY-NC-ND

SDU Link

Check access to the material in SDU Library's search engine

Cite this

Buffet, C., Belin, L., Attanasio, R., Negro, R., Hegedüs, L., Nagy, E. V., Papini, E., Perros, P., & Leenhardt, L. (2022). Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France. Annales d'Endocrinologie, 83(1), 27-34. https://doi.org/10.1016/j.ando.2021.11.002

@article{bbda8f352d01474f810e27ee4c04a1e0,

title = "Pratiques autour de l'utilisation des hormones thyro{\"i}diennes chez les patients hypothyro{\"i}diens et euthyro{\"i}diens: un tableau d{\'e}taill{\'e} des r{\'e}sultats du sondage THESIS en France",

abstract = "Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5\%) completed the survey and were included in the analysis. The vast majority (99.4\%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1\% and 14.2\% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44\% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2\%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7\%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0\%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.",

keywords = "Euthyroidism, French Endocrine Society, Hypothyroidism, Levothyroxine, Liothyronine, Survey, Adult, Drug Therapy, Combination, Female, France, Humans, Hypothyroidism/drug therapy, Male, Middle Aged, Practice Patterns, Physicians'/statistics \& numerical data, Surveys and Questionnaires, Thyroxine/administration \& dosage",

author = "Camille Buffet and Lisa Belin and Roberto Attanasio and Roberto Negro and Lazlo Heged{\"u}s and Nagy, \{Endre V.\} and Enrico Papini and Petros Perros and Laurence Leenhardt",

note = "Funding Information: We thank all members of the French Endocrine Society, who contributed to the study by answering the questionnaire. We thank Prof Nicolas Chevalier for his technical support to launch the survey in France. We thank Prof V?ronique Kerlan, president of the French Endocrine Society on behalf of this society, for its support to this project. We thank Fabiana Pani for English proofreading. We thank Fran?oise Borson Chazot, Philippe Caron and Lionel Groussin for their careful reading of the manuscript and their feedback. Funding Information: Laurence Leenhardt has received consulting fees for Merck, research funding from Merck Serono SAS (Lyon, France) and honoraria for lectures from Laboratoires Genevrier (Antibes, France). ",

year = "2022",

month = feb,

doi = "10.1016/j.ando.2021.11.002",

language = "Fransk",

volume = "83",

pages = "27--34",

journal = "Annales d'Endocrinologie",

issn = "0003-4266",

publisher = "Elsevier Masson",

number = "1",

}

Buffet, C, Belin, L, Attanasio, R, Negro, R, Hegedüs, L, Nagy, EV, Papini, E, Perros, P & Leenhardt, L 2022, 'Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France', Annales d'Endocrinologie, vol. 83, no. 1, pp. 27-34. https://doi.org/10.1016/j.ando.2021.11.002

Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France. / Buffet, Camille; Belin, Lisa; Attanasio, Roberto et al.
In: Annales d'Endocrinologie, Vol. 83, No. 1, 02.2022, p. 27-34.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens

T2 - un tableau détaillé des résultats du sondage THESIS en France

AU - Buffet, Camille

AU - Belin, Lisa

AU - Attanasio, Roberto

AU - Negro, Roberto

AU - Hegedüs, Lazlo

AU - Nagy, Endre V.

AU - Papini, Enrico

AU - Perros, Petros

AU - Leenhardt, Laurence

N1 - Funding Information: We thank all members of the French Endocrine Society, who contributed to the study by answering the questionnaire. We thank Prof Nicolas Chevalier for his technical support to launch the survey in France. We thank Prof V?ronique Kerlan, president of the French Endocrine Society on behalf of this society, for its support to this project. We thank Fabiana Pani for English proofreading. We thank Fran?oise Borson Chazot, Philippe Caron and Lionel Groussin for their careful reading of the manuscript and their feedback. Funding Information: Laurence Leenhardt has received consulting fees for Merck, research funding from Merck Serono SAS (Lyon, France) and honoraria for lectures from Laboratoires Genevrier (Antibes, France).

PY - 2022/2

Y1 - 2022/2

N2 - Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.

AB - Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.

KW - Euthyroidism

KW - French Endocrine Society

KW - Hypothyroidism

KW - Levothyroxine

KW - Liothyronine

KW - Survey

KW - Adult

KW - Drug Therapy, Combination

KW - Female

KW - France

KW - Humans

KW - Hypothyroidism/drug therapy

KW - Male

KW - Middle Aged

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Surveys and Questionnaires

KW - Thyroxine/administration & dosage

U2 - 10.1016/j.ando.2021.11.002

DO - 10.1016/j.ando.2021.11.002

M3 - Tidsskriftartikel

C2 - 34861221

AN - SCOPUS:85123683537

SN - 0003-4266

VL - 83

SP - 27

EP - 34

JO - Annales d'Endocrinologie

JF - Annales d'Endocrinologie

IS - 1

ER -

Pratiques autour de l'utilisation des hormones thyroïdiennes chez les patients hypothyroïdiens et euthyroïdiens: un tableau détaillé des résultats du sondage THESIS en France

Abstract

Bibliographical note

Funding

Keywords

Documents & Links

SDU Link

Fingerprint

Cite this